Regeneron (NASDAQ:REGN) Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in ...

Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav ...

Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN stock a Hold now.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail. ... See our analysis on Regeneron Stock Chances of A Rise for more details.

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

At levels of $515, REGN stock is trading at 14x its 2021 estimated adjusted earnings of $36.81, compared to levels of 16x seen in 2018 and over 15x seen as recently as late 2019, implying the ...

A significant trading signal occurred for Regeneron Pharma stock at a price of $501.83, after which REGN rose up to 3.2%. ... Order flow analytics, aka transaction or market flow analysis, ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

REGN Factor-Based Stock Analysis - Benjamin Graham March 12, 2025 — 12:06 pm EDT Written by John Reese for Validea -> ...